⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218486 | 1.00 | — | — | |
| SCHEMBL7593191 | 0.69 | — | — | |
| SCHEMBL7593188 | 0.69 | — | — | |
| SCHEMBL862842 | 0.67 | — | — | |
| SCHEMBL561815 | 0.67 | — | — | |
| SCHEMBL10957887 | 0.67 | — | — | |
| SCHEMBL561814 | 0.67 | — | — | |
| SCHEMBL127573 | 0.65 | — | — | |
| SCHEMBL12311134 | 0.65 | — | — | |
| SCHEMBL7592229 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178780-A1 | RAF KINASE INHIBITORS | WOOD JILL E (US) | 2012-07-12 | — | — | US | disclosed |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | RANGES GERALD | 2010-06-24 | — | — | US | disclosed |
| US-20100063088-A1 | Raf Kinase Inhibitors | WOOD JILL E | 2010-03-11 | — | — | US | disclosed |
| EP-0986382-B1 | RAF KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20050256174-A1 | Raf kinase inhibitors | BAYER HEALTHCARE LLC | 2005-11-17 | — | — | US | disclosed |
| EP-1019040-B1 | ARYL UREAS FOR THE TREATMENT OF INFLAMMATORY OR IMMUNOMODULATORY DISEASES | BAYER AG (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION (US) | 2002-08-01 | — | — | US | disclosed |
| US-6344476-B1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION | 2002-02-05 | — | — | US | disclosed |
| US-20010006975-A1 | Raf kinase inhibitors | BAYER CORPORATION AND ONYX PHARMACEUTICALS WEST HAVEN, CT AND RICHMOND, CA, RESPECTIVELY | 2001-07-05 | — | — | US | disclosed |
| EP-0986382-A4 | RAF KINASE INHIBITORS | BAYER AG (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6187799-B1 | TREATING CANCEROUS CELL GROWTH MEDIATED BY RAF KINASE BY ADMINISTERING SPECIFIED COMPOUNDS, SUCH AS 2-(METHYOXYCARBONYL),3-((4-METHYLPHENYL)UREA),5-ALKYL-THIOPHENE | ONYX PHARMACEUTICALS | 2001-02-13 | — | — | US | disclosed |
| EP-1019040-A4 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | BAYER AG (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-1019040-A1 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | Bayer Corporation (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-0986382-A1 | RAF KINASE INHIBITORS | Bayer Corporation (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998052558-A1 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | BAYER CORPORATION (US) | 1998-11-26 | — | — | WO | disclosed |
| WO-1998052559-A1 | RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 1998-11-26 | — | — | WO | disclosed |